Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on August 27, 2020, regarding Akers Biosciences, Inc. (Ticker: AKER). The filing documents the outcomes of the Company's 2020 Annual Meeting of Stockholders, which was held virtually.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Corporate Actions
- Equity Plan Amendment: Stockholders approved an amendment to the 2018 Equity Incentive Plan, increasing the number of shares available for issuance by 1,042,000, bringing the total authorized shares to 1,120,125.
- Director Elections: Four directors were elected to serve until the 2021 Annual Meeting: Christopher C. Schreiber, Joshua Silverman, Bill J. White, and Robert C. Schroeder.
- Shareholder Voting Participation: A total of 26,109,110 shares of common stock were present or represented by proxy. Additionally, holders of Series D Convertible Preferred Stock cast an aggregate of 36,973 votes.
Outlook, Risks, and Management Commentary
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The document focuses strictly on the ratification of corporate governance matters, including the appointment of Morison Cogen LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
Investor Verification Checklist
- Verify the full text of the 2018 Plan Amendment (Exhibit 10.1) to understand specific terms of the increased equity pool.
- Review the 2020 Proxy Statement for detailed biographies of the newly elected directors and further context on the voting matters.
- Confirm the impact of the Series D Convertible Preferred Stock conversion approval on future dilution, as stockholders approved issuance in excess of 20% of common stock outstanding.
- Note the advisory vote on executive compensation frequency, where stockholders selected a 3-year cycle (337,366 votes) over 1-year or 2-year options.